Literature DB >> 10955797

P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.

P M Schneider1, O Stoeltzing, J A Roth, A H Hoelscher, S Wegerer, S Mizumoto, K Becker, H J Dittler, U Fink, J R Siewert.   

Abstract

The incidence of adenocarcinomas in Barrett's esophagus has been rising in the last two decades in the United States and Western Europe for yet unknown reasons. We reported previously a large multi-institutional trial implicating p53 mutations as being involved in the pathogenesis of Barrett's cancer and representing an early marker for the malignant potential of Barrett's epithelium. A prospective study was performed to evaluate the prognostic impact of p53 mutations on survival in 59 patients with Barrett's cancer. Tissue for DNA analysis was obtained by endoscopic biopsy or immediately after surgical resections from the tumor, Barrett's epithelium, and normal stomach and esophagus. p53 mutation analysis was performed by PCR-single strand conformational polymorphism screening of exons 5-9 and DNA sequencing to unequivocally prove the presence of a mutation. p53 mutations were identified in 30 of 59 (50.8%) patients. The presence of a p53 mutation in the tumor had a significant impact on survival after curative resections (RO-resections) with cumulative 5-year survival probabilities of 68.8+/-9.7% for mutation-negative tumors and 24.3+/-9.9% for mutation-positive tumors (log rank: P < 0.001). By Cox proportional hazard analysis, including the parameters of gender, age, Union International Contre Cancer tumor stage, grading, and p53 mutation status, only Union International Contre Cancer tumor stage (P < 0.0001) and p53 mutation status (P < 0.02) were of significant independent prognostic importance. p53 mutation analysis by DNA sequencing is of significant independent prognostic importance next to histopathological tumor stage in patients with curatively resected (RO-resection) Barrett's cancer. It appears that p53 mutational status is a valuable parameter to define low-risk (p53 mutation-negative) and high-risk (p53 mutation-positive) groups for treatment failure after curative resections.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10955797

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  15 in total

1.  The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells.

Authors:  Vikas Sehdev; DunFa Peng; Mohammed Soutto; M Kay Washington; Frank Revetta; Jeffrey Ecsedy; Alexander Zaika; Tilman T Rau; Regine Schneider-Stock; Abbes Belkhiri; Wael El-Rifai
Journal:  Mol Cancer Ther       Date:  2012-02-01       Impact factor: 6.261

2.  Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study.

Authors:  R Langer; B H A Von Rahden; J Nahrig; C Von Weyhern; R Reiter; M Feith; H J Stein; J R Siewert; H Höfler; M Sarbia
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

3.  A relation between cell cycle and intestinal metaplasia in oesophageal biopsies using optical and digital microscopy.

Authors:  Miklós Máté; Béla Molnár
Journal:  Pathol Oncol Res       Date:  2015-03-05       Impact factor: 3.201

4.  Early p53 mutations in nondysplastic Barrett's tissue detected by the restriction site mutation (RSM) methodology.

Authors:  G J S Jenkins; S H Doak; A P Griffiths; N Tofazzal; V Shah; J N Baxter; J M Parry
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

5.  AXL mediates TRAIL resistance in esophageal adenocarcinoma.

Authors:  Jun Hong; Abbes Belkhiri
Journal:  Neoplasia       Date:  2013-03       Impact factor: 5.715

6.  ABL regulation by AXL promotes cisplatin resistance in esophageal cancer.

Authors:  Jun Hong; Dunfa Peng; Zheng Chen; Vikas Sehdev; Abbes Belkhiri
Journal:  Cancer Res       Date:  2012-11-01       Impact factor: 12.701

7.  Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy.

Authors:  Pierre Blanchard; Laurent Quero; Vincent Pacault; Marie-Helene Schlageter; Valerie Baruch-Hennequin; Christophe Hennequin
Journal:  BMC Cancer       Date:  2012-03-26       Impact factor: 4.430

Review 8.  Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction.

Authors:  Nicholas J Clemons; Wayne A Phillips; Reginald V Lord
Journal:  Cancer Biol Ther       Date:  2013-06-17       Impact factor: 4.742

Review 9.  Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer.

Authors:  Meilan Chen; Jizheng Huang; Zhenli Zhu; Jun Zhang; Ke Li
Journal:  BMC Cancer       Date:  2013-11-11       Impact factor: 4.430

10.  Progressive silencing of p14ARF in oesophageal adenocarcinoma.

Authors:  Yinghui Huang; Christopher J Peters; Rebecca C Fitzgerald; Ruth A Gjerset
Journal:  J Cell Mol Med       Date:  2008-04-09       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.